News · 26 weeks38-29%
2025-12-282026-06-21
Mix1990d
- SEC Filings12(63%)
- Earnings2(11%)
- Other2(11%)
- Insider2(11%)
- Leadership1(5%)
Latest news
25 items- SECCocrystal Pharma Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Cocrystal Pharma, Inc. (0001412486) (Filer)
- INSIDERSEC Form 4 filed by Chief Executive Officer Sapirstein James4 - Cocrystal Pharma, Inc. (0001412486) (Issuer)
- INSIDERSEC Form 3 filed by new insider Sapirstein James3 - Cocrystal Pharma, Inc. (0001412486) (Issuer)
- SECCocrystal Pharma Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Cocrystal Pharma, Inc. (0001412486) (Filer)
- PRCocrystal Pharma Appoints James Sapirstein, Biopharma Industry Leader with Extensive Antiviral Development Experience, as Chief Executive OfficerBOTHELL, Wash., June 03, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma Inc. (NASDAQ:COCP) ("Cocrystal" or the "Company"), a clinical-stage biotechnology company developing novel therapeutics to meet the growing need for effective, safe antiviral treatments, has appointed James Sapirstein Chief Executive Officer, effective immediately. The Company also plans to appoint Mr. Sapirstein as a member of the Board of Directors. He has extensive pharmaceutical industry leadership and development experience. Mr. Sapirstein replaces Sam Lee and Jim Martin, who served as Co-Chief Executive Officers. Sam Lee will continue as President and transition to Chief Scientific Officer, and Jim Martin will continu
- SECSEC Form DEFA14A filed by Cocrystal Pharma Inc.DEFA14A - Cocrystal Pharma, Inc. (0001412486) (Filer)
- SECSEC Form DEF 14A filed by Cocrystal Pharma Inc.DEF 14A - Cocrystal Pharma, Inc. (0001412486) (Filer)
- SECCocrystal Pharma Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Cocrystal Pharma, Inc. (0001412486) (Filer)
- PRCocrystal Pharma Announces Discovery of Pan-Viral Inhibitors Targeting Hantavirus, Bunyavirus and InfluenzaNovel, potent pan-viral inhibitors targeting the viral replication complex are under development for the treatment of hantavirus, bunyavirus and influenzaHantavirus and bunyavirus infections represent significant unmet medical needs, contribute to ongoing global outbreaks and have no approved treatments or vaccines BOTHELL, Wash., May 26, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ:COCP) ("Cocrystal" or the "Company") announces that its novel direct-acting antivirals demonstrate pan-viral activity against multiple viruses, including hantavirus, bunyavirus and influenza. These antiviral molecules target a highly conserved region of the viral replication enzyme, specifically the
- SECSEC Form 10-Q filed by Cocrystal Pharma Inc.10-Q - Cocrystal Pharma, Inc. (0001412486) (Filer)
- PRCocrystal Pharma Provides Business Update and Reports First Quarter 2026 Financial ResultsCompleted enrollment in first cohort of Phase 1b challenge study evaluating CDI-988 as a preventive and as a treatment for norovirus infection, began enrollment in prevention and treatment cohortsHighlighted CDI-988's mechanism of action and clinical advancement at ICAR 2026Granted FDA Fast Track designation for CDI-988, enabling the potential for an accelerated development pathwayReceived initial $225,000 of SBIR NIH grant for influenza A and B antiviral lead generation BOTHELL, Wash., May 15, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ:COCP) ("Cocrystal" or the "Company") provides updates on its antiviral product pipeline and business activities and reports financial results
- SECSEC Form EFFECT filed by Cocrystal Pharma Inc.EFFECT - Cocrystal Pharma, Inc. (0001412486) (Filer)
- SECCocrystal Pharma Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Cocrystal Pharma, Inc. (0001412486) (Filer)
- PRCocrystal Pharma Presentation at ICAR 2026 Highlights Mechanism of Action and Clinical Advancement of CDI-988 for the Prevention and Treatment of Norovirus InfectionOngoing Phase 1b human challenge study with oral, direct-acting protease inhibitor is designed to demonstrate proof-of-concept as a preventive and a treatmentFully enrolled first cohort is assessing the infectivity of the human challenge inoculumThere are no approved treatments or vaccines for norovirus, the leading cause of acute gastroenteritis across all age groups and geographies with a $60 billion annual economic burdenFDA Fast Track designation granted for CDI-988 underscores the lack of approved therapies and seriousness of norovirus infection BOTHELL, Wash., April 30, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ:COCP) ("Cocrystal" or the "Company") announces that the m
- SECSEC Form S-3 filed by Cocrystal Pharma Inc.S-3 - Cocrystal Pharma, Inc. (0001412486) (Filer)
- SECCocrystal Pharma Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Cocrystal Pharma, Inc. (0001412486) (Filer)
- SECSEC Form 10-K filed by Cocrystal Pharma Inc.10-K - Cocrystal Pharma, Inc. (0001412486) (Filer)
- SECCocrystal Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Cocrystal Pharma, Inc. (0001412486) (Filer)
- PRCocrystal Pharma Reports 2025 Financial Results and Provides Updates on its Antiviral Drug-Development ProgramsPhase 1b norovirus challenge study is underway at Emory University School of MedicineCDI-988 is the first oral antiviral candidate being developed for norovirus treatment and preventionNo approved treatments or vaccines are available for norovirus infection, posing a significant unmet need and contributing to a global economic burden of $60 billion annually BOTHELL, Wash., March 31, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ:COCP) ("Cocrystal" or the "Company") reports financial results for the year ended December 31, 2025, and provides updates on its antiviral product pipeline, upcoming milestones and business activities. "We are delighted to report that our norovirus human
- SECCocrystal Pharma Inc. filed SEC Form 8-K: Leadership Update8-K - Cocrystal Pharma, Inc. (0001412486) (Filer)
- SECCocrystal Pharma Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Cocrystal Pharma, Inc. (0001412486) (Filer)
- PRFirst Subjects Dosed in Cocrystal Pharma's Phase 1b Study Evaluating CDI-988 for Norovirus Prevention and TreatmentCDI-988 is a direct-acting, oral antiviral being developed for norovirusNorovirus challenge study is underway at Emory University School of Medicine to evaluate efficacy and safety of CDI-988 No approved treatments or vaccines are available for norovirus treatment and prevention, posing a significant unmet need and contributing to a global economic burden of $60 billion annually BOTHELL, Wash., March 09, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ:COCP) ("Cocrystal" or the "Company") announces the first subjects have been dosed in a Phase 1b norovirus challenge study (NCT07198139) to evaluate CDI-988 as both a preventive and treatment for norovirus infections. This cohort is t
- INSIDERDirector Frost Phillip Md Et Al bought $19,952 worth of shares (20,000 units at $1.00) (SEC Form 4)4 - Cocrystal Pharma, Inc. (0001412486) (Issuer)
- SECCocrystal Pharma Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Cocrystal Pharma, Inc. (0001412486) (Filer)
- PRCocrystal Pharma's First Oral Norovirus Protease Inhibitor CDI-988 to be Featured at the International Society for Antiviral Research Conference (ICAR) 2026CDI‑988 is the first oral antiviral drug candidate being developed for prevention and treatment of norovirus infectionsCompany to present Phase 1 data and updates from ongoing Phase 1b study conducted at Emory University School of MedicineNo approved antiviral therapies or vaccines for norovirus infections demonstrate an immediate market need BOTHELL, Wash., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ:COCP) ("Cocrystal" or the "Company") announces that initial progress of a norovirus challenge study with its direct-acting, oral protease inhibitor CDI-988 will be presented at the 39th International Conference on Antiviral Research (ICAR2026), being held April 27–May 1
COCP FAQ
5 questionsWhat does Cocrystal Pharma Inc. do?
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase 2a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also...Where does COCP stock trade?
Cocrystal Pharma Inc. (COCP) is listed on NASDAQ.What sector and industry is COCP in?
Cocrystal Pharma Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What companies are similar to COCP?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare COCP side-by-side with any of them on Quantisnow.How can I track COCP on Quantisnow?
Quantisnow aggregates Cocrystal Pharma Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow COCP to receive live email and push alerts on every new disclosure.